ClinicaliQ Trial Snapshot
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures — Recruiting • Phase III • Neurology • NCT05667142.
- XEN1101 added to existing treatment reduced seizures in patients with primary generalized tonic-clonic seizures compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS). Conditions: Primary Generalized Tonic-Clonic Seizures Interventions: XEN1101, Placebo Lead Sponsor: Xenon Pharmaceuticals Inc. Planned Enrollment: 160 participants